(“SkinBioTherapeutics” or “the Company”)
Expanded enrolment for AxisBiotix-PsTM food supplement consumer study
- Study size increased to 250 from 200, following high demand for places
- Study to commence by end February 2021
- Participants’ feedback on AxisBiotix-PsTM to be monitored through smart devices
SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that AxisBiotix Limited, a wholly owned subsidiary of the Company, has increased the size of its food supplement consumer study from 200 to 250 participants, following a high level of demand.